Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Arcturus Therapeutics Holdings Inc (NQ: ARCT )

18.69 UNCHANGED
Streaming Delayed Price Updated: 4:00 PM EDT, Sep 6, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Arcturus Therapeutics Holdings Inc

< Previous 1 2 3 4 5 6 7 8 9 Next >
Earnings Preview: Arcturus Therapeutics
Via Benzinga
Evaluating NASDAQ:ARCT for Growth Investment Opportunities.
High growth, ROE and beating expectations for NASDAQ:ARCT: growth investors may appreciate this. 
Via Chartmill
7 Under-the-Radar Biotech Stocks Gearing Up for Liftoff
Although the health innovation space can be a risky environment, undervalued biotech stocks can take some of the edge off. 
Via InvestorPlace
Arcturus Therapeutics to Present at the Barclays 26th Annual Global Healthcare Conference
From Arcturus Therapeutics Holdings Inc.
Via Business Wire
Arcturus Therapeutics Receives Orphan Medicinal Product Designation from the European Commission (EC), for ARCT-032, for the Treatment of Cystic Fibrosis
From Arcturus Therapeutics Holdings Inc.
Via Business Wire
Is NASDAQ:ARCT suited for growth investing?
Is ARCTURUS THERAPEUTICS HOLDIN (NASDAQ:ARCT) suited for growth investing? 
Via Chartmill
Wall Street Favorites: 3 Biotech Stocks With Strong Buy Ratings for February 2024
Biotech stocks are often at the forefront of innovation. These picks are worth considering for your portfolio for their growth potential. 
Via InvestorPlace
3 Tech Stocks That Could Be Multibaggers in the Making: February Edition
We have researched tech stocks for you and have found these three are likely multibaggers in the making. Considering picking them up today. 
Via InvestorPlace
Arcturus Therapeutics to Report Fourth Quarter and Full Year 2023 Financial Results and Provide Corporate Update on March 7, 2024
From Arcturus Therapeutics Holdings Inc.
Via Business Wire
New COVID-19 sa-mRNA Results from CSL and Arcturus Therapeutics Demonstrate Longer Duration of Immunity Compared to Conventional COVID-19 mRNA Vaccine Booster
From Arcturus Therapeutics
Via Business Wire
Arcturus Therapeutics: Q3 Earnings Insights
Via Benzinga
Logitech Posts Q3 Results, Joins Coinbase And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session
U.S. stock futures were mostly lower this morning, with the Dow futures falling around 20 points on Tuesday. 
Via Benzinga
Topics Stocks
Exposures US Equities
Why the growth investor may take a look at ARCTURUS THERAPEUTICS HOLDIN (NASDAQ:ARCT).
ARCTURUS THERAPEUTICS HOLDIN (NASDAQ:ARCT) may be suited for growth investing, we'll explore why in this article. 
Via Chartmill
ARCTURUS THERAPEUTICS HOLDIN (NASDAQ:ARCT) showing high EPS and FCF growth while beating expectations
Exploring growth characteristics of ARCTURUS THERAPEUTICS HOLDIN (NASDAQ:ARCT). 
Via Chartmill
CSL and Arcturus Therapeutics’ ARCT-154 Demonstrates Non-Inferiority to Original Strain and Superior Immunogenicity to Omicron BA.4/5 Variant Compared to First-Generation mRNA Vaccine Booster
From Arcturus Therapeutics
Via Business Wire
7 Undervalued Biotech Stocks That are Flying Under the Clinical Radar
While the broader healthcare sector offers myriad opportunities, these undervalued biotech picks could offer robust upside. 
Via InvestorPlace
3 Biotech Stocks With Promising Pipelines and Big Growth Potential in 2024
These biotech stocks with promising pipelines are showing some major promise and growth potential for the new year. 
Via InvestorPlace
Arcturus Therapeutics' Lung Disease Candidate Triggers Bullish Rating, Analyst Sees Over 200% Upside
Canaccord Genuity has initiated coverage on Arcturus Therapeutics Holdings Inc (NASDAQ: ARCT), a player in the genetic medicine space. 
Via Benzinga
5 Value Stocks In The Healthcare Sector
Via Benzinga
Arcturus Therapeutics to Present at the 42nd Annual J.P. Morgan Healthcare Conference
From Arcturus Therapeutics Holdings Inc.
Via Business Wire
Why the growth investor may take a look at NASDAQ:ARCT.
ARCTURUS THERAPEUTICS HOLDIN (NASDAQ:ARCT) may be suited for growth investing, we'll explore why in this article. 
Via Chartmill
Japan's Ministry of Health, Labour and Welfare Approves CSL and Arcturus Therapeutics’ ARCT-154, the First Self-Amplifying mRNA Vaccine Approved for COVID in Adults
From Arcturus Therapeutics Holdings Inc.
Via Business Wire
Arcturus Therapeutics Receives Orphan Drug Designation from the U.S. FDA for ARCT-032, for the Treatment of Cystic Fibrosis
From Arcturus Therapeutics Holdings Inc.
Via Business Wire
Why Shapeways Holdings Shares Are Trading Lower By Around 20%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session
Shares of Shapeways Holdings, Inc. (NASDAQ: SHPW) tumbled during Wednesday’s session following downbeat results. 
Via Benzinga
Target Reports Earnings Beat, Joins AST SpaceMobile, Dada Nexus And Other Big Stocks Moving Higher On Wednesday
U.S. stocks traded higher, with the Dow Jones gaining more than 100 points on Wednesday. Shares of Target Corporation (NYSE: TGT) jumped during Wednesday’s session after the company reported... 
Via Benzinga
Topics Earnings Stocks
Exposures Financial US Equities
Why CorMedix Shares Are Trading Higher By Over 19%; Here Are 20 Stocks Moving Premarket
Shares of CorMedix Inc. (NASDAQ: CRMD) surged in pre-market trading as the company posted a narrower-than-expected third-quarter loss. Cormedix posted a loss of 17 cents per share for the third... 
Via Benzinga
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Wednesday
It's time to dive into the biggest pre-market stock movers as we check out all of the hottest news worth reading about on Wednesday! 
Via InvestorPlace
Arcturus Therapeutics Announces Third Quarter 2023 Financial Update and Pipeline Progress
From Arcturus Therapeutics Holdings Inc.
Via Business Wire
The 3 Most Undervalued Biotech Stocks to Buy: November 2023
Given the undervalued biotech industry, these three undervalued biotech stocks to buy are ripe purchase targets for high-potential profits. 
Via InvestorPlace
Arcturus Therapeutics to Report Third Quarter Financial Results and Provide Corporate Update on November 14, 2023
From Arcturus Therapeutics Holdings Inc.
Via Business Wire
< Previous 1 2 3 4 5 6 7 8 9 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.